Clinical trials
Sickle Cell Anemia clinical trials
Below are recruiting sickle cell anemia clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06213402Recruiting
European registry for rare anemia disorders
This study is creating a European registry (database) to collect information about people with rare anemia disorders. By joining, you help researchers better understand these conditions and improve care for yourself and others.
Barcelona, CataloniaAges birth–100 years - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35 - NCT07708714RecruitingPhase 1/Phase 2
Hydroxyurea study for teens with sickle cell anemia
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
KampalaAges 11–18 - NCT07566494RecruitingPhase 1
Testing VAS-101 for sickle cell disease
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Bethesda, MarylandAges 18–90 - NCT07356050Recruiting
Measles vaccine study for children with sickle cell disease
This study checks if the measles vaccine works well in children with sickle cell disease. It aims to help protect children with this condition from measles.
Cincinnati, OhioAges 6 months–6 years - NCT07282210RecruitingPhase 2
New medicine for sickle cell hemolysis
This trial tests a new medicine (SIL-8301) to help control red blood cell breakdown (hemolysis) in people with sickle cell disease. It is for those who are already taking hydroxyurea and have had few pain crises but still have complications from hemolysis.
Toronto, OntarioAges 16–35 - NCT07177300RecruitingPhase 4
Hydroxyurea for sickle cell disease in children
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
Cincinnati, OhioAges 6 months+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT06941389Recruiting
Comparing stem cell transplant vs standard therapy for sickle cell disease
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
Birmingham, AlabamaAges 3–20 - NCT06761560RecruitingPhase 2/Phase 3
Hydroxyurea dosing for children with sickle cell anemia
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Montreal, QuebecAges 6 months–18 years - NCT06647979RecruitingPhase 1
Gene editing for severe sickle cell or thalassemia
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Boston, MassachusettsAges 13–40 - NCT06481306RecruitingPhase 1/Phase 2
Testing a new drug for sickle cell disease in healthy people and patients
This early-phase study tests a new drug (BMS-986470) for people with sickle cell disease who have frequent pain crises. The goal is to see if it can safely reduce crises. It includes a small group of healthy volunteers as well.
Birmingham, AlabamaAges 18 years+ - NCT06016634RecruitingPhase 2
Alendronate for bone damage in adults with sickle cell disease
This trial tests if the drug alendronate can help heal bone damage caused by sickle cell disease. It may be an option if you have this bone problem and are between 18 and 80 years old.
Sacramento, CaliforniaAges 18–80 - NCT05904093RecruitingPhase 1
Testing a new pill for sickle cell disease safety
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Bethesda, MarylandAges 18–65 - NCT05477563RecruitingPhase 3
One-time gene therapy for severe sickle cell and transfusion anemia
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
New York, New YorkAges 12–35 - NCT05285917RecruitingPhase 3
Hydroxyurea safety study for young children with sickle cell
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
LuandaAges 6 months–12 years - NCT04208529Enrolling by invitationPhase 3
Long-term follow-up after receiving CTX001 infusion
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Palo Alto, CaliforniaAges 2 years+ - NCT04093986Recruiting
Using past pregnancy records from women with sickle cell
This study looks back at past pregnancy and breastfeeding experiences in women with sickle cell disease who took hydroxyurea. It aims to better understand how hydroxyurea exposure may affect pregnancy and baby outcomes.
Cincinnati, OhioAges Any age - NCT03653338RecruitingPhase 1/Phase 2
Bone marrow transplant using donor blood to treat sickle cell
This trial tests a specific type of bone marrow transplant for people with sickle cell disease (or certain other blood disorders) who have had serious complications despite standard care. It aims to see if removing the patient’s immune cells and using a matched donor’s cells can improve outcomes and reduce complications.
Pittsburgh, PennsylvaniaAges 5–40 - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT00542230Recruiting
Blood sample study for sickle cell trait and controls
This study collects blood samples to learn more about sickle cell-related genetics and biology. You might benefit indirectly by helping researchers understand the condition, even though this is laboratory research rather than a medication trial.
Bethesda, MarylandAges 18–100 - NCT06250595Recruiting
European rare blood disorder registry
This study is building a registry of people with rare blood diseases. By joining, you help doctors learn more about these conditions and improve future care.
Barcelona, CataloniaAges Up to 100 years - NCT07090668Recruiting
Ear stimulation for pain in sickle cell disease
This trial tests a safe, non-drug device that gently stimulates the ear to help reduce pain in children with sickle cell disease who are in the hospital for a pain crisis. It may offer a new way to manage pain without extra medication.
Atlanta, GeorgiaAges 7–18 - NCT06635902RecruitingPhase 2
Citrulline for sickle cell pain crisis
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
Washington D.C., District of ColumbiaAges 4–21
Hear when a new Sickle Cell Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Sickle Cell Anemia trials by city
Studies with a site in or near these metro areas.
Sickle Cell Anemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for sickle cell anemia?
- Yes. Clin2 currently lists 46 recruiting sickle cell anemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sickle cell anemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sickle cell anemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.